Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

This study has been completed.

Study NCT00030394 Information provided by National Cancer Institute (NCI)

First Received: February 14, 2002 Last Updated: June 4, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	October 2007 (Final data collection date for primary outcome measure)

Publications:

Champagne MA, Fu CH, Chang M, Chen H, Gerbing RB, Alonzo TA, Cooley LD, Heerema NA, Oehler V, Wood C, French ME, Arceci RJ, Smith FO, Bernstein ML. Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2011 Apr 4; [Epub ahead of print]

Champagne MA, Fu C, Chang M, et al.: Imatinib in children with newly diagnosed chronic phase chronic myelogenous leukemia (CP CML): AAML0123 COG study. [Abstract] Blood 108 (11): A-2140, 2006.